Nuvo drug delivery, inflammation, neurology news

Nuvo said it plans to spin out its drug development business into a stand-alone, publicly traded company. Nuvo would become a profitable commercial company focused on its Pennsaid diclofenac franchise. The spinout would focus on developing Nuvo’s pipeline, including WF10. The tetrachlorodecaoxygen chlorite matrix is in Phase II testing to treat allergic rhinitis. If approved by shareholders, Nuvo expects the split to complete early next year. ...